Sage Therapeutics, Inc.
SAGE · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $571,009 | $491,771 | $329,959 | $441,261 |
| - Cash | $67,487 | $45,224 | $81,021 | $99,627 |
| + Debt | $11,421 | $11,855 | $11,836 | $10,274 |
| Enterprise Value | $514,943 | $458,402 | $260,774 | $351,908 |
| Revenue | $31,660 | $14,063 | $12,816 | $11,871 |
| % Growth | 125.1% | 9.7% | 8% | – |
| Gross Profit | $31,715 | $13,408 | $11,327 | $6,593 |
| % Margin | 100.2% | 95.3% | 88.4% | 55.5% |
| EBITDA | -$54,095 | -$67,455 | -$80,211 | -$100,947 |
| % Margin | -170.9% | -479.7% | -625.9% | -850.4% |
| Net Income | -$49,652 | -$62,214 | -$95,778 | -$93,551 |
| % Margin | -156.8% | -442.4% | -747.3% | -788.1% |
| EPS Diluted | -0.79 | -1.01 | -1.57 | -1.53 |
| % Growth | 21.8% | 35.7% | -2.6% | – |
| Operating Cash Flow | -$58,690 | -$81,728 | -$66,560 | -$82,365 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$58,690 | -$81,728 | -$66,560 | -$82,365 |